FIH TO CLINICAL ACCELERATION CONCURRENT Allogenic vs Autologous Debate: Developing Cell Therapies with an Eye to Patient Access
Friday, June 2, 2023 08:00 AM - 09:00 AM
Amphitheatre Bleu
FROM FIH TO CLINICAL ACCELERATION
Concurrent
Co-Chairs
Julie Allickson, PhD, Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine, Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics, USA
Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania, USA
Speakers
David Sourdive, PhD, Co-founder, Executive Vice President CMC and Manufacturing, Cellectis, France
Catherine Bollard, MBChB, MD, Children's National Hospital, USA
Matthew Hewitt, PhD, Vice President, Technical Officer CGT & Biologics, Charles River Laboratories, USA
Saad Kenderian, MB ChB, Assistant Professor, Medicine, Oncology and Immunology, Mayo Clinic, USA
Allogeneic or “off-the-shelf” chimeric antigen receptor T-cell therapies have translated to clinic and the hope is that they will lower cost of treatment, enhance scaling and offer a better therapeutic cell base. In this debate, experts share their perspectives on whether this hope reflects the direction of the field.
Julie Allickson, PhD, Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine, Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics, USA
Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania, USA
Speakers
David Sourdive, PhD, Co-founder, Executive Vice President CMC and Manufacturing, Cellectis, France
Catherine Bollard, MBChB, MD, Children's National Hospital, USA
Matthew Hewitt, PhD, Vice President, Technical Officer CGT & Biologics, Charles River Laboratories, USA
Saad Kenderian, MB ChB, Assistant Professor, Medicine, Oncology and Immunology, Mayo Clinic, USA
Allogeneic or “off-the-shelf” chimeric antigen receptor T-cell therapies have translated to clinic and the hope is that they will lower cost of treatment, enhance scaling and offer a better therapeutic cell base. In this debate, experts share their perspectives on whether this hope reflects the direction of the field.
Julie Allickson
Director, Mayo Clinic Center for Regenerative Biotherapeutics Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine
Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Chair
Director, Mayo Clinic Center for Regenerative Biotherapeutics Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine
Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Chair
Bruce Levine PhD
Barbara and Edward Netter Professor in Cancer Gene Therapy
University of Pennsylvania
Chair
Barbara and Edward Netter Professor in Cancer Gene Therapy
University of Pennsylvania
Chair
Matthew Hewitt PhD
Vice President, Technical Officer CGT & Biologics
Charles River Laboratories
Speaker
Vice President, Technical Officer CGT & Biologics
Charles River Laboratories
Speaker